Limits...
Improved therapeutic effectiveness by combining liposomal honokiol with cisplatin in lung cancer model.

Jiang QQ, Fan LY, Yang GL, Guo WH, Hou WL, Chen LJ, Wei YQ - BMC Cancer (2008)

Bottom Line: The present study showed that liposomal honokiol alone resulted in effective suppression of the tumor growth, and that the combined treatment with honokiol plus DDP had the enhanced inhibition of the tumor growth and resulted in a significant increase in life span.The more apparent apoptotic cells in the tumors treated with honokiol plus DDP was found in fluorescent in situ TUNEL assay, compared with the treatment with control groups.In addition, the combination of honokiol and DDP apparently reduced the number of vessels by immunolabeling of CD31 in the tissue sections, compared with control groups.

View Article: PubMed Central - HTML - PubMed

Affiliation: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, PR China. ivy77qqwfy@163.com

ABSTRACT

Background: Honokiol is a major bioactive compound extracted from Magnolia. The present study was designed to determine whether liposomal honokiol has the antitumor activity against human lung cancer as well as potentiates the antitumor activity of cisplatin in A549 lung cancer xenograft model, if so, to examine the possible mechanism in the phenomenon.

Methods: human A549 lung cancer-bearing nude mice were treated with liposomal honokiol, liposomal honokiol plus DDP or with control groups. Apoptotic cells and vessels were evaluated by fluorescent in situ TUNEL assay and by immunohistochemistry with an antibody reactive to CD31 respectively.

Results: The present study showed that liposomal honokiol alone resulted in effective suppression of the tumor growth, and that the combined treatment with honokiol plus DDP had the enhanced inhibition of the tumor growth and resulted in a significant increase in life span. The more apparent apoptotic cells in the tumors treated with honokiol plus DDP was found in fluorescent in situ TUNEL assay, compared with the treatment with control groups. In addition, the combination of honokiol and DDP apparently reduced the number of vessels by immunolabeling of CD31 in the tissue sections, compared with control groups.

Conclusion: In summary, our data suggest that honokiol alone had the antitumor activity against human lung cancer in A549 lung cancer xenograft model, and that the combination of honokiol with DDP can enhance the antitumor activity, and that the enhanced antitumor efficacy in vivo may in part result from the increased induction of the apoptosis and the enhanced inhibition of angiogenesis in the combined treatment. The present findings may be of importance to the further exploration of the potential application of the honokiol alone or the combined approach in the treatment of lung carcinoma.

Show MeSH

Related in: MedlinePlus

The representative experiment of inhibition of the angiogenesis within tumors. Mice bearing the established tumors were administered i.p. with liposomal honokiol (25 mg/kg) every day for 21 days, and/or cisplatin (5 mg/kg, i.p. twice a week for two weeks).or liposome or PBS alone. Vessel density was determined by counting per high-power field in the sections stained with an antibody reactive to CD31, as described in Materials and Methods. The combination of liposomal honokiol and DDP (A) apparently reduced the number of the microvessels, compared with the control groups, including liposomal honokiol (B), cisplatin (C), liposome (D) or PBS (E) alone. Vessel density was determined by counting per high-power (F).Column, the mean of the microvessels per high-power field; bars, ± SD. H and L mean liposomal honokiol and liposome alone respectively.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2543046&req=5

Figure 2: The representative experiment of inhibition of the angiogenesis within tumors. Mice bearing the established tumors were administered i.p. with liposomal honokiol (25 mg/kg) every day for 21 days, and/or cisplatin (5 mg/kg, i.p. twice a week for two weeks).or liposome or PBS alone. Vessel density was determined by counting per high-power field in the sections stained with an antibody reactive to CD31, as described in Materials and Methods. The combination of liposomal honokiol and DDP (A) apparently reduced the number of the microvessels, compared with the control groups, including liposomal honokiol (B), cisplatin (C), liposome (D) or PBS (E) alone. Vessel density was determined by counting per high-power (F).Column, the mean of the microvessels per high-power field; bars, ± SD. H and L mean liposomal honokiol and liposome alone respectively.

Mentions: Having witnessed apparent antitumor activity in A549 human lung cancer model, we further quantified vessel density as measures of angiogenesis by immunolabeling of CD31 in tissue sections. The combination of liposomal honokiol and DDP apparently reduced the number of vessels compared with control groups (Figure 2), including liposome, PBS, liposomal honokiol, DDP alone (P < 0.05). Angiogenesis was also inhibited in the treatment with honokiol or DDP alone (Figure 2).


Improved therapeutic effectiveness by combining liposomal honokiol with cisplatin in lung cancer model.

Jiang QQ, Fan LY, Yang GL, Guo WH, Hou WL, Chen LJ, Wei YQ - BMC Cancer (2008)

The representative experiment of inhibition of the angiogenesis within tumors. Mice bearing the established tumors were administered i.p. with liposomal honokiol (25 mg/kg) every day for 21 days, and/or cisplatin (5 mg/kg, i.p. twice a week for two weeks).or liposome or PBS alone. Vessel density was determined by counting per high-power field in the sections stained with an antibody reactive to CD31, as described in Materials and Methods. The combination of liposomal honokiol and DDP (A) apparently reduced the number of the microvessels, compared with the control groups, including liposomal honokiol (B), cisplatin (C), liposome (D) or PBS (E) alone. Vessel density was determined by counting per high-power (F).Column, the mean of the microvessels per high-power field; bars, ± SD. H and L mean liposomal honokiol and liposome alone respectively.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2543046&req=5

Figure 2: The representative experiment of inhibition of the angiogenesis within tumors. Mice bearing the established tumors were administered i.p. with liposomal honokiol (25 mg/kg) every day for 21 days, and/or cisplatin (5 mg/kg, i.p. twice a week for two weeks).or liposome or PBS alone. Vessel density was determined by counting per high-power field in the sections stained with an antibody reactive to CD31, as described in Materials and Methods. The combination of liposomal honokiol and DDP (A) apparently reduced the number of the microvessels, compared with the control groups, including liposomal honokiol (B), cisplatin (C), liposome (D) or PBS (E) alone. Vessel density was determined by counting per high-power (F).Column, the mean of the microvessels per high-power field; bars, ± SD. H and L mean liposomal honokiol and liposome alone respectively.
Mentions: Having witnessed apparent antitumor activity in A549 human lung cancer model, we further quantified vessel density as measures of angiogenesis by immunolabeling of CD31 in tissue sections. The combination of liposomal honokiol and DDP apparently reduced the number of vessels compared with control groups (Figure 2), including liposome, PBS, liposomal honokiol, DDP alone (P < 0.05). Angiogenesis was also inhibited in the treatment with honokiol or DDP alone (Figure 2).

Bottom Line: The present study showed that liposomal honokiol alone resulted in effective suppression of the tumor growth, and that the combined treatment with honokiol plus DDP had the enhanced inhibition of the tumor growth and resulted in a significant increase in life span.The more apparent apoptotic cells in the tumors treated with honokiol plus DDP was found in fluorescent in situ TUNEL assay, compared with the treatment with control groups.In addition, the combination of honokiol and DDP apparently reduced the number of vessels by immunolabeling of CD31 in the tissue sections, compared with control groups.

View Article: PubMed Central - HTML - PubMed

Affiliation: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, PR China. ivy77qqwfy@163.com

ABSTRACT

Background: Honokiol is a major bioactive compound extracted from Magnolia. The present study was designed to determine whether liposomal honokiol has the antitumor activity against human lung cancer as well as potentiates the antitumor activity of cisplatin in A549 lung cancer xenograft model, if so, to examine the possible mechanism in the phenomenon.

Methods: human A549 lung cancer-bearing nude mice were treated with liposomal honokiol, liposomal honokiol plus DDP or with control groups. Apoptotic cells and vessels were evaluated by fluorescent in situ TUNEL assay and by immunohistochemistry with an antibody reactive to CD31 respectively.

Results: The present study showed that liposomal honokiol alone resulted in effective suppression of the tumor growth, and that the combined treatment with honokiol plus DDP had the enhanced inhibition of the tumor growth and resulted in a significant increase in life span. The more apparent apoptotic cells in the tumors treated with honokiol plus DDP was found in fluorescent in situ TUNEL assay, compared with the treatment with control groups. In addition, the combination of honokiol and DDP apparently reduced the number of vessels by immunolabeling of CD31 in the tissue sections, compared with control groups.

Conclusion: In summary, our data suggest that honokiol alone had the antitumor activity against human lung cancer in A549 lung cancer xenograft model, and that the combination of honokiol with DDP can enhance the antitumor activity, and that the enhanced antitumor efficacy in vivo may in part result from the increased induction of the apoptosis and the enhanced inhibition of angiogenesis in the combined treatment. The present findings may be of importance to the further exploration of the potential application of the honokiol alone or the combined approach in the treatment of lung carcinoma.

Show MeSH
Related in: MedlinePlus